Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Bernhard; D. Zahrieh; J. J. Zhang; G. Martinelli; R. Basser; C. Hürny; J. F. Forbes; S. Aebi; W. Yeo; B. Thürlimann; M. D. Green; M. Colleoni; R. D. Gelber; M. Castiglione-Gertsch; K. N. Price; A. Goldhirsch; A. S. Coates

doi:10.1038/sj.bjc.6604092

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

J. Bernhard, D. Zahrieh, J. J. Zhang, G. Martinelli, R. Basser, C. Hürny, J. F. Forbes, S. Aebi, W. Yeo, B. Thürlimann, M. D. Green, M. Colleoni, R. D. Gelber, M. Castiglione-Gertsch, K. N. Price, A. Goldhirsch, A. S. Coates

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P

Original language	English
Pages (from-to)	25-33
Number of pages	9
Journal	British Journal of Cancer
Volume	98
Issue number	1
DOIs	https://doi.org/10.1038/sj.bjc.6604092
Publication status	Published - Jan 15 2008

Keywords

Adaptation
Adjuvant chemotherapy
Breast cancer
Quality of life
Quality-adjusted survival

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1038/sj.bjc.6604092

Cite this

Bernhard, J., Zahrieh, D., Zhang, J. J., Martinelli, G., Basser, R., Hürny, C., Forbes, J. F., Aebi, S., Yeo, W., Thürlimann, B., Green, M. D., Colleoni, M., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., & Coates, A. S. (2008). Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British Journal of Cancer, 98(1), 25-33. https://doi.org/10.1038/sj.bjc.6604092

Bernhard, J, Zahrieh, D, Zhang, JJ, Martinelli, G, Basser, R, Hürny, C, Forbes, JF, Aebi, S, Yeo, W, Thürlimann, B, Green, MD, Colleoni, M, Gelber, RD, Castiglione-Gertsch, M, Price, KN, Goldhirsch, A & Coates, AS 2008, 'Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer', British Journal of Cancer, vol. 98, no. 1, pp. 25-33. https://doi.org/10.1038/sj.bjc.6604092

@article{1be822acbd2f461585e8611b7716d0d7,

title = "Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer",

abstract = "Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P",

keywords = "Adaptation, Adjuvant chemotherapy, Breast cancer, Quality of life, Quality-adjusted survival",

author = "J. Bernhard and D. Zahrieh and Zhang, {J. J.} and G. Martinelli and R. Basser and C. H{\"u}rny and Forbes, {J. F.} and S. Aebi and W. Yeo and B. Th{\"u}rlimann and Green, {M. D.} and M. Colleoni and Gelber, {R. D.} and M. Castiglione-Gertsch and Price, {K. N.} and A. Goldhirsch and Coates, {A. S.}",

year = "2008",

month = jan,

day = "15",

doi = "10.1038/sj.bjc.6604092",

language = "English",

volume = "98",

pages = "25--33",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

AU - Bernhard, J.

AU - Zahrieh, D.

AU - Zhang, J. J.

AU - Martinelli, G.

AU - Basser, R.

AU - Hürny, C.

AU - Forbes, J. F.

AU - Aebi, S.

AU - Yeo, W.

AU - Thürlimann, B.

AU - Green, M. D.

AU - Colleoni, M.

AU - Gelber, R. D.

AU - Castiglione-Gertsch, M.

AU - Price, K. N.

AU - Goldhirsch, A.

AU - Coates, A. S.

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P

AB - Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P

KW - Adaptation

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Quality of life

KW - Quality-adjusted survival

UR - http://www.scopus.com/inward/record.url?scp=38049033043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049033043&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604092

DO - 10.1038/sj.bjc.6604092

M3 - Article

C2 - 18043579

AN - SCOPUS:38049033043

VL - 98

SP - 25

EP - 33

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this